Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SER Stock Forecast 2026-2027
$2.13
Current Price
$31.94M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SER Price Targets
+416.4%
To High Target of $11.00
+346.0%
To Median Target of $9.50
+275.6%
To Low Target of $8.00
SER Price Momentum
-0.5%
1 Week Change
+1.4%
1 Month Change
-60.3%
1 Year Change
+11.5%
Year-to-Date Change
-73.1%
From 52W High of $7.92
+74.6%
From 52W Low of $1.22
📊 TOP ANALYST CALLS
Did SER Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Serina is one of their latest high-conviction picks.
Latest SER Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, SER has a bullish consensus with a median price target of $9.50 (ranging from $8.00 to $11.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $2.13, the median forecast implies a 346.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SER Analyst Ratings
2
Buy
0
Hold
0
Sell
SER Price Target Range
Low
$8.00
Average
$9.50
High
$11.00
Current: $2.13
Latest SER Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SER.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 1, 2026 | BTIG | Buy | Initiates | $N/A | |
| Aug 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 14, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Mar 11, 2025 | Jones Trading | Buy | Initiates | $N/A |
Serina Therapeutics Inc. (SER) Competitors
The following stocks are similar to Serina based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SER
Serina Therapeutics
mkt cap
32.09M
Serina Therapeutics Inc. (SER) Financial Data
Serina Therapeutics Inc. has a market capitalization of $31.94M with a P/E ratio of 1.6x. The company generates $130,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -18,803.1% and return on equity of -221.9%.
Valuation Metrics
Market Cap
$31.94M
Enterprise Value
$15.70M
P/E Ratio
1.6x
PEG Ratio
0.1x
Price/Sales
245.7x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-18,803.1%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+76.8%
Current Ratio
4.2x
Debt/Equity
18.9x
ROE
-221.9%
ROA
-89.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Serina Therapeutics Inc. (SER) Business Model
About Serina Therapeutics Inc.
What They Do
Develops polymer-based therapeutics for medical challenges.
Business Model
The company employs a biopharmaceutical model, focusing on developing proprietary polyoxazoline (POZ) polymer technology to enhance drug delivery and efficacy. By improving the pharmacokinetics and safety profiles of its drug candidates, Serina Therapeutics aims to monetize its innovations through licensing agreements, partnerships with larger pharmaceutical companies, and potential future product sales.
Additional Information
Serina Therapeutics is positioned in the biotechnology sector, targeting treatment for neurological diseases, cancer, and autoimmune conditions. Its innovative approach to drug delivery could significantly impact patient outcomes and aligns with the growing trend towards precision medicine, addressing unmet medical needs in the market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Mr. Steven A. Ledger
Country
United States
IPO Year
2024
Website
serinatherapeutics.comSerina Therapeutics Inc. (SER) Latest News & Analysis
Latest News
Quick Summary
Serina Therapeutics (NYSE: SER) announced the completion of sentinel dosing in Cohort 1 of its Phase 1b trial for SER-252, targeting advanced Parkinson's disease.
Why It Matters
Completion of sentinel dosing in a Phase 1b trial for SER-252 signals progress in drug development for Parkinson's, potentially impacting Serina's valuation and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
18 days ago
Quick Summary
Gannet BioChem has formed a development partnership with Serina Therapeutics (NYSE: SER), focusing on therapies utilizing Serina's POZ Platform™ technology.
Why It Matters
Gannet BioChem's partnership with Serina Therapeutics could enhance innovation and growth potential in biotech, impacting stock performance and market sentiment for both companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2 months ago
Quick Summary
A Phase 1b clinical study of SER-252 for advanced Parkinson's disease has started, with TFL data from the SAD study expected in the first half of 2027.
Why It Matters
The initiation of the SER-252 clinical study indicates potential advancements in Parkinson's treatment, which could impact stock valuations and market confidence in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Serina Therapeutics (NYSE: SER) announced it will present data on its novel POZ Platform lipid nanoparticles at a summit, showing no antibody response in rats, indicating potential for improved drug delivery.
Why It Matters
Serina Therapeutics' breakthrough in lipid nanoparticles could enhance drug delivery and reduce immunogenicity, potentially leading to more effective therapies and increased market value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
3 months ago
Quick Summary
Serina Therapeutics, Inc. (NYSE American: SER) has received approval from NYSE American for its business plan to regain compliance with listing standards.
Why It Matters
Serina Therapeutics’ compliance with NYSE standards signals potential stability and growth, which can positively influence investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Serina Therapeutics, Inc. (NYSE American: SER) will have CEO Steve Ledger present at the 38th Annual Roth Conference in Dana Point, CA, on March 24, 2026, at 11:30 a.m. PST.
Why It Matters
Steve Ledger's presentation at a major conference could signal upcoming developments for Serina Therapeutics, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SER Stock
What is Serina Therapeutics Inc.'s (SER) stock forecast for 2027?
Based on our analysis of 1 Wall Street analysts, Serina Therapeutics Inc. (SER) has a median price target of $9.50. The highest price target is $11.00 and the lowest is $8.00.
Is SER stock a good investment in 2027?
According to current analyst ratings, SER has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SER stock?
Wall Street analysts predict SER stock could reach $9.50 in the next 12 months. This represents a 346.0% increase from the current price of $2.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Serina Therapeutics Inc.'s business model?
The company employs a biopharmaceutical model, focusing on developing proprietary polyoxazoline (POZ) polymer technology to enhance drug delivery and efficacy. By improving the pharmacokinetics and safety profiles of its drug candidates, Serina Therapeutics aims to monetize its innovations through licensing agreements, partnerships with larger pharmaceutical companies, and potential future product sales.
What is the highest forecasted price for SER Serina Therapeutics Inc.?
The highest price target for SER is $11.00 from at , which represents a 416.4% increase from the current price of $2.13.
What is the lowest forecasted price for SER Serina Therapeutics Inc.?
The lowest price target for SER is $8.00 from at , which represents a 275.6% increase from the current price of $2.13.
What is the overall SER consensus from analysts for Serina Therapeutics Inc.?
The overall analyst consensus for SER is bullish. Out of 1 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.50.
How accurate are SER stock price projections?
Stock price projections, including those for Serina Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:55 AM UTC